Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FDC101
- Development stage
- Phase 2
- Lead developer
- MediGene
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Intradermal
01
Overview
FDC101 is an investigational **dendritic cell vaccine** composed of autologous dendritic cells loaded with the tumor-associated antigens WT1 (Wilms tumor 1) and PRAME (Preferentially Expressed Antigen in Melanoma). It is developed for **acute myeloid leukemia (AML)** and administered to stimulate the patient’s immune response against residual leukemia cells, aiming to improve overall survival, progression-free survival, and control of minimal residual disease in AML patients following standard therapy[1]. The vaccine is administered as a maintenance or consolidation immunotherapy over a 2-year period in a clinical trial setting.
- Other names
- WT1 and PRAME RNA-loaded dendritic cell vaccineWT-1 and PRAME RNA-loaded dendritic cell vaccineWT 1 and PRAME RNA-loaded dendritic cell vaccine
02
Targets
PRAME (Preferentially expressed antigen in melanoma)γδ TCR (T-cell receptor)WT1 (Wilms tumor protein)
Beyond the preview
Go deeper on FDC101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FDC101.